Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children
- 1 March 1997
- journal article
- clinical trial
- Published by Wiley in Acta Paediatrica
- Vol. 86 (3) , 319-320
- https://doi.org/10.1111/j.1651-2227.1997.tb08898.x
Abstract
In a randomized, double-blind clinical trial, the efficacy and safety of norfloxacin were compared with nalidixic acid in the treatment of shigellosis in children. Out of 59 cases, Shigella spp. were isolated from 8 cases in the nalidixic acid group and 14 cases in the norfloxacin group. The norfloxacin group had significantly less duration of diarrhoea and presence of blood in stool as compared to the nalidixic acid group. No joint problem was encountered in this study at up to 4 months follow-up. Norfloxacin is safe and effective and showed no cartilage toxicity on short-term follow-up.Keywords
This publication has 7 references indexed in Scilit:
- Single-dose ciprofloxacin for shigellosis in adultsJournal of Infection, 1992
- Randomized Clinical Trial of Norfloxacin for ShigellosisThe American Journal of Tropical Medicine and Hygiene, 1991
- Relative efficacy of trimethoprim-sulfamethoxazole and nalidixic acid for acute invasive diarrheaAntimicrobial Agents and Chemotherapy, 1987
- EPIDEMIC OF DYSENTERY IN WEST BENGAL: CLINICIANS' ENIGMAThe Lancet, 1984
- In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogensAntimicrobial Agents and Chemotherapy, 1983
- Juvenile canine drug-induced arthropathy: Clinicopathological studies on articular lesions caused by oxolinic and pipemidic acidsToxicology and Applied Pharmacology, 1979
- Antibiotic Susceptibility Testing by a Standardized Single Disk MethodAmerican Journal of Clinical Pathology, 1966